In 111 DAC

Drug Profile

In 111 DAC

Alternative Names: DTPA-adenosylcobalamin

Latest Information Update: 10 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; Naviscan PET Systems
  • Class Heavy metals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 10 Dec 2007 In 111 DAC is still in phase I trials for Diagnostic Imaging in USA
  • 01 Dec 2005 Mayo Clinic and Naviscan PET Systems have entered into licensing agreement for use of In 111 DAC as molecular imaging agent in cancer patients
  • 29 Nov 2005 Clinical trials in Diagnostic imaging in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top